147 related articles for article (PubMed ID: 22376154)
1. CXCR4 inhibitors: tumor vasculature and therapeutic challenges.
de Nigris F; Schiano C; Infante T; Napoli C
Recent Pat Anticancer Drug Discov; 2012 Sep; 7(3):251-64. PubMed ID: 22376154
[TBL] [Abstract][Full Text] [Related]
2. The CXCL12 (SDF-1)/CXCR4 chemokine axis: Oncogenic properties, molecular targeting, and synthetic and natural product CXCR4 inhibitors for cancer therapy.
Zhou Y; Cao HB; Li WJ; Zhao L
Chin J Nat Med; 2018 Nov; 16(11):801-810. PubMed ID: 30502762
[TBL] [Abstract][Full Text] [Related]
3. CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization.
Liekens S; Schols D; Hatse S
Curr Pharm Des; 2010; 16(35):3903-20. PubMed ID: 21158728
[TBL] [Abstract][Full Text] [Related]
4. The chemokine receptors CXCR4/CXCR7 and their primary heterodimeric ligands CXCL12 and CXCL12/high mobility group box 1 in pancreatic cancer growth and development: finding flow.
Shakir M; Tang D; Zeh HJ; Tang SW; Anderson CJ; Bahary N; Lotze MT
Pancreas; 2015 May; 44(4):528-34. PubMed ID: 25872129
[TBL] [Abstract][Full Text] [Related]
5. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
6. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands.
Zabel BA; Wang Y; Lewén S; Berahovich RD; Penfold ME; Zhang P; Powers J; Summers BC; Miao Z; Zhao B; Jalili A; Janowska-Wieczorek A; Jaen JC; Schall TJ
J Immunol; 2009 Sep; 183(5):3204-11. PubMed ID: 19641136
[TBL] [Abstract][Full Text] [Related]
7. Biological/pathological functions of the CXCL12/CXCR4/CXCR7 axes in the pathogenesis of bladder cancer.
Nazari A; Khorramdelazad H; Hassanshahi G
Int J Clin Oncol; 2017 Dec; 22(6):991-1000. PubMed ID: 29022185
[TBL] [Abstract][Full Text] [Related]
8. Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy.
Zhou W; Guo S; Liu M; Burow ME; Wang G
Curr Med Chem; 2019; 26(17):3026-3041. PubMed ID: 28875842
[TBL] [Abstract][Full Text] [Related]
9. Drug Design Targeting the CXCR4/CXCR7/CXCL12 Pathway.
Xu D; Li R; Wu J; Jiang L; Zhong HA
Curr Top Med Chem; 2016; 16(13):1441-51. PubMed ID: 26369824
[TBL] [Abstract][Full Text] [Related]
10. Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.
Chen FH; Fu SY; Yang YC; Wang CC; Chiang CS; Hong JH
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):777-84. PubMed ID: 23601898
[TBL] [Abstract][Full Text] [Related]
11. Inflammatory CXCL12-CXCR4/CXCR7 axis mediates G-protein signaling pathway to influence the invasion and migration of nasopharyngeal carcinoma cells.
Qiao N; Wang L; Wang T; Li H
Tumour Biol; 2016 Jun; 37(6):8169-79. PubMed ID: 26715277
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of CXCL12/CXCR4 axis as a potential targeted therapy of advanced gastric carcinoma.
Xue LJ; Mao XB; Ren LL; Chu XY
Cancer Med; 2017 Jun; 6(6):1424-1436. PubMed ID: 28544785
[TBL] [Abstract][Full Text] [Related]
13. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?
Duda DG; Kozin SV; Kirkpatrick ND; Xu L; Fukumura D; Jain RK
Clin Cancer Res; 2011 Apr; 17(8):2074-80. PubMed ID: 21349998
[TBL] [Abstract][Full Text] [Related]
14. [Advance of research on SDF-1/CXCR4 axis and angiogenesis in leukemia--review].
Bao CH; He QT
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Apr; 16(2):447-51. PubMed ID: 18426684
[TBL] [Abstract][Full Text] [Related]
15. Stromal cell-derived factor-1 (SDF-1) as a target in liver diseases.
Liepelt A; Tacke F
Am J Physiol Gastrointest Liver Physiol; 2016 Aug; 311(2):G203-9. PubMed ID: 27313175
[TBL] [Abstract][Full Text] [Related]
16. Can inhibition of the SDF-1/CXCR4 axis eradicate acute leukemia?
Tavor S; Petit I
Semin Cancer Biol; 2010 Jun; 20(3):178-85. PubMed ID: 20637871
[TBL] [Abstract][Full Text] [Related]
17. Tannic acid is an inhibitor of CXCL12 (SDF-1alpha)/CXCR4 with antiangiogenic activity.
Chen X; Beutler JA; McCloud TG; Loehfelm A; Yang L; Dong HF; Chertov OY; Salcedo R; Oppenheim JJ; Howard OM
Clin Cancer Res; 2003 Aug; 9(8):3115-23. PubMed ID: 12912963
[TBL] [Abstract][Full Text] [Related]
18. Drug design strategies focusing on the CXCR4/CXCR7/CXCL12 pathway in leukemia and lymphoma.
Barbieri F; Bajetto A; Thellung S; Würth R; Florio T
Expert Opin Drug Discov; 2016 Nov; 11(11):1093-1109. PubMed ID: 27598329
[TBL] [Abstract][Full Text] [Related]
19. The role of SDF-1-CXCR4/CXCR7 axis in biological behaviors of adipose tissue-derived mesenchymal stem cells in vitro.
Li Q; Zhang A; Tao C; Li X; Jin P
Biochem Biophys Res Commun; 2013 Nov; 441(3):675-80. PubMed ID: 24184476
[TBL] [Abstract][Full Text] [Related]
20. Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner.
Guleng B; Tateishi K; Ohta M; Kanai F; Jazag A; Ijichi H; Tanaka Y; Washida M; Morikane K; Fukushima Y; Yamori T; Tsuruo T; Kawabe T; Miyagishi M; Taira K; Sata M; Omata M
Cancer Res; 2005 Jul; 65(13):5864-71. PubMed ID: 15994964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]